Maze Therapeutics (NASDAQ:MAZE) Sees Unusually-High Trading Volume – Should You Buy?

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) saw unusually-high trading volume on Friday . Approximately 583,220 shares changed hands during mid-day trading, a decline of 8% from the previous session’s volume of 634,280 shares.The stock last traded at $24.7240 and had previously closed at $24.82.

Analyst Ratings Changes

Several research firms recently commented on MAZE. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, BTIG Research reiterated a “buy” rating and issued a $46.00 price objective on shares of Maze Therapeutics in a report on Wednesday, August 12th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics Price Performance

The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. The firm’s fifty day moving average price is $28.33 and its 200-day moving average price is $30.50. The stock has a market cap of $1.37 billion, a P/E ratio of -9.73 and a beta of 2.17.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting analysts’ consensus estimates of ($0.76). Analysts forecast that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Insider Activity

In related news, CMO Harold Bernstein sold 16,142 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $27.61, for a total value of $445,680.62. Following the sale, the chief marketing officer directly owned 16,142 shares of the company’s stock, valued at $445,680.62. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the business’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $27.58, for a total value of $206,850.00. Following the transaction, the insider owned 26,250 shares in the company, valued at approximately $723,975. This represents a 22.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 219,317 shares of company stock valued at $5,989,040. Insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Maze Therapeutics

A number of large investors have recently made changes to their positions in MAZE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Maze Therapeutics during the first quarter valued at approximately $57,000. Goldman Sachs Group Inc. bought a new position in Maze Therapeutics in the 1st quarter worth $145,000. Rhumbline Advisers purchased a new stake in shares of Maze Therapeutics in the 1st quarter worth about $80,000. Geode Capital Management LLC boosted its stake in shares of Maze Therapeutics by 8.8% during the 2nd quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock valued at $2,838,000 after purchasing an additional 18,773 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Maze Therapeutics by 387.0% during the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after purchasing an additional 3,371 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.